September 2013

Filed Pursuant to Rule 433

Registration Statement No. 333-190464

September 9, 2013

2

2

This

presentation

contains

forward-looking

statements

under

the

meaning

of

the

Private

Securities

Litigation

Reform

Act

of

1995.

These

statements

give

our

current

expectations

or

forecasts

and

use

words

such

as

“anticipate,”

“estimate,”

"expect,"

“believe,”

and

other

words

of

similar

meaning.

Any

or

all

of

the

forward-looking

statements

in

this

presentation

may

turn

out

to

be

wrong.

They

can

be

affected

by

inaccurate

assumptions

we

might

make

or

by

known

or

unknown

risks

and

uncertainties

including

but

not

limited

to,

the

efficacy

of

our

product

candidates,

their

efficacy

at

acceptable

dosage

levels,

the

ability

to

raise

capital

when

needed

and

on

reasonable

terms,

projections

of

potential

commercial

sales

of

company

products,

the

results

and

progress

of

clinical

trials,

developing

the

necessary

manufacturing

processes

and

gaining

all

necessary

regulatory

approvals,

both

in

the

United

States

and

internationally.

Consequently,

no

forward-looking

statement

can

be

guaranteed

and

actual

results

may

differ

materially.

Additional

information

concerning

factors

that

could

cause

actual

results

to

materially

differ

from

those

in

the

forward-looking

statements

are

contained

in

our

most

recent

reports

to

the

Securities

and

Exchange

Commission

including

our

Form

10-Q,

8-K

and

10-K

reports.

However,

we

undertake

no

obligation

to

publicly

update

forward-looking

statements,

whether

as

a

result

of

new

information,

future

events

or

otherwise.

We

note

these

factors

for

investors

as

permitted

by

the

Private

Securities

Litigation

Reform

Act

of

1995.

The

information

in

this

document

has

been

prepared

solely

for

informational

purposes

and

does

not

constitute

an

offer

to

sell

or

the

solicitation

of

an

offer

to

purchase

any

securities

from

any

entities

described

herein.

Any

such

offer

will

be

made

solely

by

means

of

the

prospectus

contained

in

the

registration

statement

(the

"Registration

Statement")

filed

by

OXiGENE,

Inc.

(the

"Company")

with

the

Securities

and

Exchange

Commission

(the

"SEC").

The

information

contained

herein

may

not

be

used

in

connection

with

an

offer

or

solicitation

by

anyone

in

any

jurisdiction

in

which

such

offer

or

solicitation

is

not

permitted

by

law

or

in

which

the

person

making

the

offer

or

solicitation

is

not

qualified

to

do

so

or

to

any

person

to

whom

it

is

unlawful

to

much

such

offer or solicitation.

INVESTING

IS

SPECULATIVE

AND

INVOLVES

RISK

OF

LOSS.

YOU

SHOULD

REVIEW

CAREFULLY

THE

REGISTRATION

STATEMENT,

INCLUDING

THE

DESCRIPTION

OF

THE

RISKS

AND

OTHER

TERMS

BEFORE

MAKING

A

DECISION

TO

INVEST.

The

Company

has

filed

a

Registration

Statement

(including

a

prospectus)

with

the

SEC

for

the

offering

to

which

this

presentation

relates.

Before

you

invest,

you

should

read

the

prospectus

contained

in

the

Registration

Statement,

the

information

incorporated

by

reference

into

the

Registration

Statement,

and

other

documents

the

Company

has

filed

with

the

SEC

for

more

complete

information

about

the

Company

and

the

offering.

You

may

get

these

documents

for

free

by

visiting

EDGAR

on

the

SEC

website

at

http://www.sec.gov

Alternatively,

the

Company

or

the

placement

agent

participating

in

the

offering

will

arrange

to

send

you

the

prospectus contained in the Registration Statement if you request it by calling H.C. Wainwright & Co., LLC at (212) 356-0500.

Safe Harbor And Free Writing Prospectus Statement

Safe Harbor And Free Writing Prospectus Statement

OXiGENE, Inc. (OXGN) Corporate Snapshot

OXiGENE, Inc. (OXGN) Corporate Snapshot

Development-stage biotechnology company

Lead

product

candidate:

ZYBRESTAT

®

A vascular disrupting agent (VDA) being developed

primarily as an adjunctive cancer therapy which

has shown utility and tolerability to date in

combination

with

Avastin

®

and other cancer drugs

for ovarian cancer and other solid tumors

Follow-on product: OXi4503

A

2

nd

–

generation,

dual-mechanism

VDA

being

developed for acute myeloid leukemia (AML)

Robust intellectual property (IP) portfolio

consists of more than 120 patents worldwide

3

OXiGENE Leadership Team

OXiGENE Leadership Team

4

5

5

After many years of research,

After many years of research,

we believe ZYBRESTAT

we believe ZYBRESTAT

®

®

may

may

become the first

become the first

commercialized VDA…

commercialized VDA…

*

*

*

6

6

…

…

attracting the support of

attracting the support of

numerous prestigious

numerous prestigious

foundations, non-profit

foundations, non-profit

research institutions and “big

research institutions and “big

pharma”

pharma”

companies.

companies.

*

*

7

7

Where is the Opportunity?

Where is the Opportunity?

Significant Therapeutic and Commercial Potential

Potential to significantly improve outcomes in solid tumor indications

Example: Antisoma received $75M upfront and $915 M in potential

development-based milestones for ASA404 from Novartis

Challenging Development History Limits Competition

Apart from OXiGENE only 3 other companies are known to be currently

developing

VDAs,

none

of

which

have

progressed

to

the

submission

stage

OXiGENE

believes

it

has

determined

the

optimal

way

ZYBRESTAT

®

should be developed and brought to the market

ZYBRESTAT

®

May Become the First Commercialized VDA

Clinically

meaningful

activity

with

no

significant

safety

issues

to

date

Previously identified cardiovascular response was found to be easily

managed with no abrogation of the anti-tumor effects

8

8

OXiGENE’s

OXiGENE’s

ZYBRESTAT

ZYBRESTAT

®

®

(fosbretabulin,

(fosbretabulin,

CA4P)

CA4P)

Established Safety Profile (>400 patients)

No cumulative toxicities or cytotoxic-like side-effects

Manageable, transient mild-to-moderate hypertension

Manageable, transient myelosuppression with chemotherapy

Demonstrated Vascular Disrupting Activity

Single agent activity with partial and complete responses in solid tumors

Positive

results

in

combination

with

Avastin

®

(bevacizumab)

Positive

results

in

combination

with

Paraplatin

®

/

Taxol

®

Robust Intellectual Property (IP)

Protected by both composition-of-matter and method-of-use patents

Exclusive, worldwide license to the combretastatins discovered and

isolated by researchers at Arizona State University (ASU)

9

9

Unique, Dual Mechanism of Action

Tubulin-mediated cell shape change of endothelial and leukemic cells

Metabolized by oxidative enzymes (e.g., tyrosinases and peroxidases)

into an orthoquinone species with direct cytotoxic effects on tumor cells

Compelling Preclinical and Early Clinical Data

Recommended dose, objective responses and significant blood flow

reductions shown in Ph 1/2 studies in refractory solid tumors

Demonstrated near-complete elimination of FLT-3 mutated human AML

(leukemic clone) in systemic xenograft in SCID mouse model

Robust Intellectual Property (IP)

Protected by both composition-of-matter and method-of-use patents

Exclusive, worldwide license to the combretastatins discovered and

isolated by researchers at Arizona State University (ASU)

OXiGENE’s OXi4503: A 2nd-Generation VDA

OXiGENE’s OXi4503: A 2nd-Generation VDA

10

10

OXiGENE’s Late-Stage Development Pipeline

OXiGENE’s Late-Stage Development Pipeline

ZYBRESTAT

®

Combination Therapy

Preclinical

Phase 1

Phase 2

Phase 3

With Paraplatin

®

(carboplatin) / Taxol

®

(paclitaxel) in anaplastic thyroid cancer

(ATC)

With Avastin

®

(bevacizumab) in ovarian

cancer

With Votrient

®

(pazopanib) in ovarian

cancer

With Taxol

®

(paclitaxel) in ovarian cancer

ZYBRESTAT

®

Single-Agent Therapy

Preclinical

Phase 1

Phase 2

Phase 3

Carcinoid syndrome

OXi4503 Single-Agent Therapy

Preclinical

Phase 1

Phase 2

Phase 3

Refractory acute myelogenous leukemia

(AML)

Ph. 2/3 completed

Ph. 2 ongoing

Ph. 2 planned

Ph. 2 planned

Ph. 1 ongoing

Ph. 1b/2 planned

Pre-EU MAA

11

11

OXiGENE (OXGN) Investment Thesis

OXiGENE (OXGN) Investment Thesis

Compelling Valuation

Currently trading at a market cap of less than $10 million

Leveraging $200+ million previously invested primarily in VDA development

Cost-Efficient and Risk-Mitigated Development Strategy

Ongoing and planned Ph 2 trials supported by foundations, non-profit research

institutions and larger pharmaceutical companies

Significant Potential Value-Creating Events on the Horizon

Enrollment complete for ongoing Avastin

®

+/-

ZYBRESTAT

®

Ph 2 in ovarian

cancer; Preliminary results expected 1H14

Potential initiation of Taxol

®

+/-

ZYBRESTAT

®

and Votrient

®

+/-

ZYBRESTAT

®

Ph 2 trials in ovarian cancer, as well as a Ph 1a/2b trial in carcinoid syndrome

Completion of enrollment for OXi4503 Ph 1 trial in AML

Actively pursuing development and commercialization agreements with

established industry leaders

12

12

Vascular Disrupting

Vascular Disrupting

Agents (VDAs)

Agents (VDAs)

Denying Tumors Oxygen

Denying Tumors Oxygen

and Vital Nutrients

and Vital Nutrients

*

*

*

*

*

*

*

13

13

About Vascular Disrupting Agents (VDAs)

About Vascular Disrupting Agents (VDAs)

Proven Mechanism of Action

VDAs cut off blood supply to tumors, effectively

‘starving' them of oxygen and nutrients

Reducing blood supply is a proven mechanism

used by  commercialized anti-VEGF drugs such

as Avastin

®

(bevacizumab) to treat cancer

Targeted Impact

VDAs disrupt blood flow and vasculature only

within tumors, sparing normal cells and organs

Broad Therapeutic Utility

Potentially useful in a wide range of tumors

Potentially improve clinical outcomes when

used in combination with other types of anti-

cancer therapies

Tumor Blood Flow Before VDA

Tumor Blood Flow After VDA

14

14

Product

Developer

Partner

Status

In Active Development

ZYBRESTAT

®

OXiGENE

Unpartnered;

Licensed from 

Arizona State

University (ASU)

and BMS

Currently in pre-MAA stage for ATC in EU

Completed Ph 2b/3a with Paraplatin

®

(carboplatin) / Taxol

®

(paclitaxel) in

anaplastic thyroid cancer (ATC)

Currently in Ph 2 with Avastin

®

(bevacimuzab) in ovarian cancer

Planned Ph 2 with Votrient

®

(pazopanib) in ovarian cancer

Planned Ph 2 with Taxol

®

(paclitaxel) in ovarian cancer

Planned Ph 1/2 trial in carcinoid syndrome (IP from AngioGene)

OXi4503

OXiGENE

Unpartnered;

ASU License

Currently in Phase 1 in acute myelogenous leukemia

BNC105

Bionomics

Unpartnered

Currently in Ph 2 in combination with chemotherapy in both renal

cell and

ovarian cancers

NPI-2358

(plinabulin)

Nereus

Unpartnered

Completed Ph 1 and Ph 2 clinical trials for solid tumors and NSCLC

(combination with docetaxel); no ongoing trials

Crolibulin

EpiCept

Immune Pharma

Ltd.

Currently in Phase 1/2 in combination with cisplatin in solid tumors with

focus on ATC

No Longer in Active Development

AVE8062

Ajinomoto

SanofiAventis

Active but limited IP

ASA404

Antisoma

Novartis

Failed in Ph 3

Denibulin

AngioGene

MediciNova

Cardiac toxicity in Ph 2

ZD6126

AstraZeneca

AngioGene

Cardiac toxicity in Ph 2

VDA Competitive Landscape

VDA Competitive Landscape

15

15

ZYBRESTAT

ZYBRESTAT

®

®

Program

Program

in Ovarian Cancer

in Ovarian Cancer

*

*

*

*

*

*

*

*

16

16

Why Ovarian Cancer?

Why Ovarian Cancer?

Aggressive, stealthy cancer

~22,000 new cases in the U.S. annually,

~220,000 new cases worldwide

Over 60% of patients have distant spread

at diagnosis resulting in poor prognosis

Dire need for better therapies

Highly lethal cancer that is responsible

for the deaths of approximately 14,000

women in the U.S. each year

Rapid resistance to existing FDA-

approved treatments ultimately limits

their effectiveness

5-year survival rates of only 47%, largely

unchanged since the 1990s

•

Annual Incidence And Mortality Rates

of Female Cancers Worldwide

•

Ovarian Cancer Spread at Diagnosis

17

17

Risk-Mitigated, Cost Effective Development

Risk-Mitigated, Cost Effective Development

18

18

Avastin

Avastin

®

®

(bevacizumab) +/-

(bevacizumab) +/-

ZYBRESTAT

ZYBRESTAT

®

®

Co-Sponsored by Gynecologic Oncology Group (GOG),

National Cancer Institute (NCI), and Genentech / Roche

Ongoing Ph 2 trial (GOG186I) in ovarian cancer

First randomized combination study of Anti-VEGF + VDA compounds

2nd-

or 3rd-line therapy for platinum-resistant ovarian cancer

Primary endpoint: Median progression free survival (PFS)

Goal: Improvement  in PFS from 50% (Avastin

®

) to 65% (Combination)

Enrollment complete at 107 patients at 80+ clinical sites; preliminary

results expected 1H14

Rationale: Positive Ph 1 and preclinical trial results

Disease stabilization in 9/14 (60%) treated patients who had failed

multiple prior therapies

19

19

Votrient

Votrient

®

®

(pazopanib)

(pazopanib)

+/-

+/-

ZYBRESTAT

ZYBRESTAT

®

®

Potentially Sponsored by UK Non-Profit Cancer Research

Organization and Drug Manufacturers Involved

Planned Randomized, Placebo-controlled Ph 2 trial

Up to 120 patients with platinum-resistant ovarian cancer

Primary endpoint: Median progression free survival (PFS)

Initiation expected 1H14

Rationale: Positive Ph 1 and Preclinical Trial Results

Positive

Ph

1

results

with

Avastin

®

+

ZYBRESTAT

®

Anti-angiogenic

multi-kinase

inhibitors

+

ZYBRESTAT

®

significantly

reduced tumor growth rates in preclinical tumor models

OXiGENE’s Estimated Cost: < $1M

20

20

Weekly Taxol

Weekly Taxol

®

®

(paclitaxel) +/-

(paclitaxel) +/-

ZYBRESTAT

ZYBRESTAT

®

®

OXiGENE’s Estimated Cost: ~$1M w/ or ~$8M w/o Co-Sponsor

21

21

*

*

*

*

*

*

*

*

*

*

ZYBRESTAT

ZYBRESTAT

®

®

Program

Program

in Carcinoid Syndrome

in Carcinoid Syndrome

*

*

*

**

*

*

*

22

22

Carcinoid Syndrome

Carcinoid Syndrome

Slow-Growing, Biologically

Active GI Tumors

Neuroendocrine tumors (NETs) that

overproduce biologically active

substances such as serotonin

Causes debilitating symptoms,

including episodic flushing, diarrhea,

wheezing, and potentially carcinoid

heart disease

Limited Therapeutic Options

Somatostatin

analogues

such

as

Sandostatin

®

(octreotide)

help

to

control symptoms, but the effect is often only temporary

Non-responders are limited to surgical resection and/or chemotherapy,

for which patients are often ineligible

23

23

Sandostatin

Sandostatin

®

®

(octreotide) +/-

(octreotide) +/-

ZYBRESTAT

ZYBRESTAT

®

®

Planned Ph. 1b/2a Self-Controlled Study

20 Sandostatin

®

-refractory carcinoid syndrome patients with 

increased biomarker (5-HIAA and/or chromogranin A) levels

Primary endpoints: Biomarker (5-HIAA and/or chromogranin A) levels

Secondary endpoints: Symptom control, QoL

Rationale: Positive Preclinical Results, Potentially Rapid

Development Pathway, Robust Intellectual Property

Positive preclinical data in prolactinoma and insulinoma models

Potentially rapid readout and development based on biomarkers

Exclusive, worldwide licensing agreement with Angiogene

Pharmaceuticals for the use of VDAs in the treatment of carcinoid

syndrome and other neuroendocrine tumors (NETs)

OXiGENE’s Estimated Cost: ~$3M

24

24

ZYBRESTAT

ZYBRESTAT

®

®

Program

Program

in Anaplastic Thyroid

in Anaplastic Thyroid

Cancer (ATC)

Cancer (ATC)

*

**

*

*

*

*

*

25

25

ZYBRESTAT

ZYBRESTAT

®

®

in Anaplastic Thyroid Cancer

in Anaplastic Thyroid Cancer

Completed Randomized Ph. 2/3 (FACT) Trial Results

80 patients with biopsy-proven ATC at 40 clinical sites

Paraplatin

®

(carboplatin)

/

Taxol

®

(paclitaxel)

+/-

ZYBRESTAT

®

Primary endpoint: Median survival: 5.2 vs. 4.0 months (NS), HR 0.72

Secondary endpoints: 1-year survival 26 vs. 9%; OR rate 20 vs. 16%

Target 1H16 EMA marketing authorization in EU

Potential

for

approval

via

“Exceptional

Circumstances”

pathway

May not require additional clinical data

Anaplastic Thyroid Cancer (ATC)

Highly aggressive and lethal cancer with limited

treatment options

~2,000 total patients annually in the US and EU

Orphan drug status in both the US and EU

OXiGENE’s Estimated Cost: ~$5M remaining

26

26

Paraplatin

®

/

Taxol

®

+

ZYBRESTAT (N=55)

Paraplatin

®

/

Taxol

®

(N=25)

Median Survival

(95% CI)

5.2 months

(3.1, 9.0)

4.0 months

(2.8, 6.2)

One-year Survival

25.5%

8.7%

Hazard Ratio

(95%CI)

0.72 (0.43, 1.20)

28% Risk Reduction

•

Survival Time (Months)

Results from Ph 2/3 (FACT) Study in ATC

Results from Ph 2/3 (FACT) Study in ATC

27

27

OXi4503 Program

OXi4503 Program

in Acute Myelogenous

in Acute Myelogenous

Leukemia (AML)

Leukemia (AML)

*

*

*

*

*

*

*

28

28

OXi4503 in Acute Myelogenous Leukemia

OXi4503 in Acute Myelogenous Leukemia

Ongoing Ph 1 Dose-Escalation Study

Co-sponsored by the University of Florida, the Leukemia and Lymphoma

Society

Up to 36 relapsed and refractory acute myelogenous leukemia (AML) or

myelodysplastic syndrome

patients 

Primary endpoint: Recommended dose

Secondary endpoint: Hematologic responses

Rationale: Positive Preclinical Trial Results and Robust

Intellectual Property

Demonstrated near-complete elimination of FLT-3 mutated human AML

(leukemic clone) in systemic xenograft in SCID mouse model

Composition-of-matter and method-of-use patents for myeloid-lineage

leukemias

29

29

OXiGENE (OXGN)

OXiGENE (OXGN)

Corporate Summary

Corporate Summary

*

*

*

*

*

*

*

*

30

30

Financial Overview

Financial Overview

Cost-Efficient, “Virtual Company”

Infrastructure

Cash: $7.7M (2Q13), projected to last into 2Q14

Raised $6.1M in early 2013 via ATM and PIPE

Reduced expenses by more than 30% in 2012

Debt: $0M (2Q13)

Common Stock: 2.7M outstanding (6.8M fully diluted)

Prioritized Spending Needs

Avastin

®

combo (GOG0186I) in ovarian cancer (<$1M remaining)

Votrient

®

combo in ovarian cancer (<$1M in future spending)

Taxol

®

combo in ovarian cancer ($1-8M in  future spending)

EU

MAA

filing

for

Paraplatin

®

/

Taxol

®

combo

in

ATC

(~$5M,

some

of

which may be recovered via commercialization of registration lots)

Carcinoid syndrome Ph 1 program (~$3M)

31

31

Robust Intellectual Property Portfolio

Robust Intellectual Property Portfolio

ZYBRESTAT®

United States

Europe

Japan

Composition of Matter: fosbretabulin

tromethamine

September 2021

US 7659261, 7524832 &

7659262

September 2021

EPO 1320534

September 2021

JP 4149804

Method of modulating tumor growth

or metastasis by administration of fosbretabulin

and paclitaxel

December 2021

US 6,538,038

N/A

N/A

Method of treating NET including carcinoid

tumor symptoms by administering fosbretabulin

June 2033

PCT* pending

June 2033

PCT *pending

June 2033

PCT* pending

OXi4503

Composition of Matter: OXi4503 –

salt form

including potassium

October 2021

US 7,078,552

April 2021

EPO 1278758

February 2020

pending

Method of treating myeloid neoplasm by

administering OXi4503

November 2028

November 2028

November 2028

JP 5302328

•

*A Patent Cooperation Treaty (PCT) application establishes a filing date in all 148 contracting states.

OXiGENE is the owner or exclusive licensee

of more than 120 patents worldwide

32

32

2013

2H13: Ongoing

dialogue with EMA

regarding EU MAA for

ZYBRESTAT

®

in ATC

2H15: Initial data from

potential Ph 2 Taxol

®

and

Votrient

®

+/-

ZYBRESTAT

®

combo trials

2H15: Potential EMA MAA

submission for ZYBRESTAT

®

in ATC

2014

2015

2016

2017

Numerous Upcoming Catalysts

Numerous Upcoming Catalysts

2017: Potential FDA

NDA submission for

Avastin

®

+/-

ZYBRESTAT

®

combo in

ovarian cancer

1H14: Preliminary data from

ongoing Ph 2 Avastin

®

+/-

ZYBRESTAT

®

combo trial (GOG-

186I)

1H14: Potential initiation of Ph

2 Taxol

®

+/-

ZYBRESTAT

®

combo trial

1H14: Potential initiation of Ph

2 Votrient

®

+/-

ZYBRESTAT

®

combo trial

2016 : Potential EU MAA approval for

ZYBRESTAT

®

in ATC

2016: Potential final data from Ph 2

Taxol

®

and Votrient

®

+/-

ZYBRESTAT

®

combo trials

2016: Potential final data from Ph 3

Avastin

®

+/-

ZYBRESTAT

®

combo

trials

33

33

OXiGENE (OXGN) Investment Thesis

OXiGENE (OXGN) Investment Thesis

Compelling Valuation

Currently trading at a market cap of less than $10 million

Leveraging $200+ million previously invested primarily in VDA development

Cost-Efficient and Risk-Mitigated Development Strategy

Ongoing and planned Ph 2 trials supported by foundations, non-profit research

institutions and larger pharmaceutical companies

Significant Potential Value-Creating Events on the Horizon

Enrollment complete for  ongoing Avastin

®

+/-

ZYBRESTAT

®

Ph 2 in ovarian

cancer -

preliminary results expected 1H14

Potential initiation of Taxol

®

+/-

ZYBRESTAT

®

and Votrient

®

+/-

ZYBRESTAT

®

Ph 2 trials in ovarian cancer, as well as a Ph 1a/2b trial in carcinoid syndrome

Completion of enrollment for OXi4503 Ph 1 trial in AML

Actively pursuing development and commercialization agreements with

established industry leaders